Navigation Links
BioMarin Initiates Phase 1/2 Trial for BMN 701 for the Treatment of Pompe Disease
Date:1/19/2011

60;There are two main forms of Pompe disease: adult onset with an incidence of one in 57,000 births and infantile onset with an incidence of one in 138,000 births.  Prognosis with standard of care is stabilization of the disease or minor improvements for the majority of adult onset patients.About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Other product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in clinical development for the treatment of MPS IVA, PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU, BMN 701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA) in Phase 1/2 development for the treatment of Pompe disease, and BMN 673, a poly ADP-ribose polymerase (PARP) inhibitor in Phase 1/2 development for the treatment of genetically-defined cancers. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

Forward-Looking StatementThis press
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
2. BioMarin Announces FDA Approval for Kuvan
3. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
4. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
5. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
6. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
7. BioMarin Acquires Huxley Pharmaceuticals, Inc.
8. BioMarin to Present at the Oppenheimer Healthcare Conference
9. BioMarin Announces Third Quarter 2009 Financial Results
10. BioMarin to Acquire LEAD Therapeutics
11. BioMarin to Present at the Credit Suisse Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... R.I. , July 10, 2014 CVS Caremark ... board of directors has approved a quarterly dividend of $0.275 ... dividend is payable on August 1, 2014, to holders of ... CVS Caremark is dedicated to helping people ... pharmacy company in the United States . ...
(Date:1/15/2014)... 15, 2014 Sono-Tek Corporation (OTC BB: SOTK) today announced ... 2013, compared to sales of $2,202,000 for the prior year ... quarter has also shown growth over the preceding quarter,s sales, ... this fiscal year. Markets that experienced sales increases over the ...
(Date:1/15/2014)... Most osteoporosis patients want a choice in the medication ... by Mission Pharmacal Company. The survey, conducted by ... community, revealed that 74 percent of osteoporosis patients surveyed ... other than a pill or a tablet. ...
Breaking Medicine Technology:Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3
... UPPSALA, Sweden, April 14 Oasmia,Pharmaceutical, Uppsala, Sweden, ... FDA of Paclical(R) for the treatment of ovarian ... FDA to expedite and,optimize drug development and upon ... (Logo: http://www.newscom.com/cgi-bin/prnh/20070918/273312 ...
... Entry into Oncology Market; Rosetta to Receive Milestones ... DIEGO, PHILADELPHIA and REHOVOT, Israel, April 13 ... company, and Rosetta Genomics Ltd. (Nasdaq: ... announced the execution of a license and collaboration ...
Cached Medicine Technology:Oasmia: FDA Grants Paclical(R) Orphan Drug Designation for Ovarian Cancer in the USA 2Prometheus and Rosetta Genomics Announce License and Collaboration Agreement 2Prometheus and Rosetta Genomics Announce License and Collaboration Agreement 3Prometheus and Rosetta Genomics Announce License and Collaboration Agreement 4Prometheus and Rosetta Genomics Announce License and Collaboration Agreement 5Prometheus and Rosetta Genomics Announce License and Collaboration Agreement 6
(Date:7/11/2014)... London, UK (PRWEB) July 11, 2014 ... segment of the in-vitro diagnostics industry, which is expected ... next ten years. The sector owes its growth to ... threat to people’s health worldwide and a major factor ... diagnostic technologies, threat of bio-terrorism, and a broader availability ...
(Date:7/11/2014)... 2014 The report, “Specialty Synthetic ... & Geography - 2018,” defines and segments the ... an analysis and forecast of the volumes and ... (Para aramids, meta aramids, UHMW Polyethylene, carbon fiber, ... fiber, PBI fiber, PBO fiber, and liquid crystal ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 Datalogic brings ... in improving sanitation hospital wide. With their new ... spread of disease, like the devastating MRSA, which claimed ... Gryphon GD4400-HC 2D and the Gryphon GM4400-HC ... barcodes and can even read barcodes off of troublesome ...
(Date:7/11/2014)... 11, 2014 Operators and ... billion in fuel costs now that model ... current GHG standards are phasing in ... upon themselves to install new features into ... reduction technologies , 2.    Efficient driveline components which ...
(Date:7/11/2014)... -- Children who have emergency surgery on weekends ... even death than those who have weekday surgeries, ... Johns Hopkins researchers noted that the risk of ... on nearly 440,000 simple emergency surgeries that children ... period. The surgeries are considered generally safe ...
Breaking Medicine News(10 mins):Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 2Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 3Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 2Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 3Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 4Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 2Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 3Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 2Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 3Health News:Emergency Surgeries on Weekends Riskier for Kids: Study 2
... Job Creation and Employee Training, DURHAM, N.C., March ... one of the Triangle,s top employers for making the,community ... and Wake Tech Community College selected Parata for the ... the region,s,talent pool., Parata grew from a startup ...
... Issues Temporary Restraining Order, ALLEGAN, Mich., March 11 ... that it has received final approval,from the U.S. Food ... (ANDA) for Clobetasol Propionate Foam, 0.05%., The product ... to severe dermatosis of the scalp. Sales for the ...
... CEO and Founder of,Ingenious Med and a practicing ... serve on the Benchmarks Committee for the Society ... of the Benchmarks Committee,will make recommendations to the ... and review. This will include shaping processes for ...
... and Children,s Healthcare of Atlanta are teaming up with ... to make kidney transplants more tolerable for children. ... Childrens Hospital in Los Angeles and Lucile Packard Children,s ... of kidney transplants in children. , The National ...
... at Georgetown University, has been named a member of ... Crawford is in the Tumor Biology Program at ... University Medical Center. , The Bouchet Society is named ... United States (Physics, Yale University, 1876). The Society ...
... PHILADELPHIA World-class cancer researchers whose science has significantly ... be recognized April 12-16, 2008, by the American Association ... at the San Diego Convention Center in San Diego, ... annually by the AACR, the worlds oldest and largest ...
Cached Medicine News:Health News:Parata Systems Named '2008 Business Champion' 2Health News:Perrigo Company Receives Final Approval on Clobetasol Propionate Foam 2Health News:Perrigo Company Receives Final Approval on Clobetasol Propionate Foam 3Health News:Dr. Steve Liu, CEO of Ingenious Med, Joins Benchmarks Committee at SHM 2Health News:NIH grant to Emory and pediatric partners aims to improve kidney transplants for children 2Health News:Georgetown U student selected for prestigious Bouchet Society 2Health News:Leading researchers honored for progress in cancer prevention, detection and treatment 2Health News:Leading researchers honored for progress in cancer prevention, detection and treatment 3Health News:Leading researchers honored for progress in cancer prevention, detection and treatment 4Health News:Leading researchers honored for progress in cancer prevention, detection and treatment 5Health News:Leading researchers honored for progress in cancer prevention, detection and treatment 6Health News:Leading researchers honored for progress in cancer prevention, detection and treatment 7
Perforated or Rod Top, Free Standing or Wall Mounted, Storage Cubby Optional, Polypropylene Construction...
... metal frames ensure cleanroom ... cleanliness and chemical resistance. ... with user-friendly pnuematic controls ... Fixed footring standard. Five ...
... Cleanroom-grade vinyl curtains or parting ... steel support frame to form ... that meets cleanliness to Class ... filter/fan units, lights, and ionizers ...
Inquire...
Medicine Products: